Ainos CEO looks to advance AI nose technology in 2025

Ainos (AIMD) provided a letter to shareholders from its Chairman, President, and CEO Chun-Hsien Tsai, which read in part, “As 2024 draws to a close, I am honored to share Ainos, Inc.’s significant achievements this year. Guided by our commitment to innovation, excellence, and corporate responsibility, we continue to push the boundaries of technology, bringing real, meaningful change to healthcare, industry, and beyond. I firmly believe that every step we take at Ainos contributes to the betterment of humanity and the world…As we enter 2025, we are committed to accelerating growth and innovation with a clear focus on the following: 1. Advancing AI Nose Technology : Drive mass production and market deployment for smart healthcare, woman’s health, senior care, and industrial applications. Over H1 2025, we will advance mass production for our senior care and smart manufacturing projects and commence a clinical study for our second-generation Flora. 2. Progressing VELDONA Clinical Trials : Submit Investigational New Drug applications to the U.S. FDA for Sjogren’s syndrome and HIV-related oral warts by H2 2025 . 3. Strengthening Strategic Partnerships : Expand our collaboration with Mitsubishi Tanabe Pharma and pursue new opportunities for AI Nose and VELDONA technologies worldwide. 4. Expanding Our IP Portfolio : Secure and develop additional intellectual property to strengthen our technological leadership and long-term value. Join Our Journey in Creating a Better Future Together At Ainos, we are not only focused on delivering business success but are deeply committed to improving human health, ensuring environmental sustainability, and enhancing quality of life globally. Moving forward, we will continue driving innovation, unlocking new market opportunities, and delivering tangible contributions to society.”